Výsledky vyhledávání - "David Bing Zhen"

Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA)

Autor: E. Gabriela Chiorean, Aude Chapuis, Andrew L. Coveler, Cecilia CS Yeung, Ted Gooley, David Bing Zhen, Gentry Teng King, Lindsay Marie Hannan, Stacey A. Cohen, Rachael A Safyan, Anthony Germani, Susan Ra, Jennifer Casserd, Thomas Schmitt, Philip D Greenberg

Publikováno v: Journal of Clinical Oncology. 41:TPS779-TPS779

TPS779 Background: PDA has a low tumor mutational burden and an immunosuppressive microenvironment. Targeting overexpressed self-antigens with adoptive, genetically engineered, high affinity T cells may overcome immunosuppression (Stromnes I, Immunol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a42a731ca5e89decbfcf87adec003bf7
https://doi.org/10.1200/jco.2023.41.4_suppl.tps779

Zobrazit plný text záznamu

Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification

Autor: Diane M. Simeone, Kara Schradle, Robert W. Cowan, Heather Cameron, Sara L. Manning, David Bing Zhen, Erica D. Pratt, Andrew D. Rhim, Edmund Qiao

Publikováno v: Analytical Chemistry. 91:7516-7523

Oncology research is increasingly incorporating molecular detection of circulating tumor DNA (ctDNA) as a tool for cancer surveillance and early detection. However, non-invasive monitoring of conditions with low tumor burden remains challenging, as t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d9b6e572404d95ed1e9014a3eb48873
https://doi.org/10.1021/acs.analchem.8b01605

Zobrazit plný text záznamu

Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04)

Autor: Vaibhav Sahai, David Bing Zhen, Oxana V. Crysler, Shaalan Shaalan Beg, Thomas Enzler, Kent A. Griffith, Mark Zalupski

Publikováno v: Journal of Clinical Oncology. 40:4094-4094

4094 Background: Patients (pts) with advanced biliary tract cancers (BTC) have a poor prognosis despite systemic chemotherapy. Gemcitabine (G) and cisplatin (C) is a standard first-line systemic therapy with a reported overall response rate (ORR) of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b232860ac3668b3f50134dfe4530425
https://doi.org/10.1200/jco.2022.40.16_suppl.4094

Zobrazit plný text záznamu

Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer

Autor: Sahai, David Bing Zhen, Diane M. Simeone, Sara L. Manning, Heather Cameron, Erica D. Pratt, Gunchick, Kara Schradle, Andrew D. Rhim, Robert W. Cowan

PurposeThe clinical utility of circulating tumor DNA (ctDNA) has been shown in advanced pancreatic ductal adenocarcinoma (PDA). However, diagnostic sensitivity of many ctDNA assays is low in resectable and locally advanced disease, where tumor burden

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4455b823a67344af2d66c369a8666437
https://doi.org/10.1101/2021.03.28.437388

Zobrazit plný text záznamu

Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001

Autor: David Bing Zhen, Martin Whittle, Paul S. Ritch, Howard S. Hochster, Andrew L. Coveler, Ben George, Andrew Eugene Hendifar, Tomislav Dragovich, Steven Green, Barbara Dion, Amy C. Stoll-D'Astice, Arthur Lee, Shelley M. Thorsen, Adam Rosenthal, Sunil R. Hingorani, E. Gabriela Chiorean

Publikováno v: Journal of Clinical Oncology. 40:576-576

576 Background: Stromal HA poses a physical barrier and protects tumor cells from immune surveillance. PEGPH20 is a pegylated, human recombinant PH20 hyaluronidase that remodels tumor stroma. Preclinical studies of PEGPH20 showed improved infiltratio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::341a17798019ec30dce5b23b97b6a38c
https://doi.org/10.1200/jco.2022.40.4_suppl.576

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání